Global Typhoid Antibody Testing Market Size Likely to Grow at a CAGR of 11.48% By 2034

Market Size and Growth

As per the Typhoid Antibody Testing Market size conducted by the CMI Team, the global Typhoid Antibody Testing Market is expected to record a CAGR of 11.48% from 2025 to 2034. In 2025, the market size is projected to reach a valuation of USD 1.31 Billion. By 2034, the valuation is anticipated to reach USD 3.49 Billion.

Overview

The growing need for fast, affordable, and deployable diagnostics is driving growth in the typhoid antibody testing market. The global prevalence of typhoid and paratyphoid fever is largely restricted to low- and middle-income countries, especially in South Asia, Southeast Asia, and sub-Saharan Africa, where continued transmission is driven by poor sanitation, unsafe drinking water, and limited healthcare infrastructure. Public health programs and health systems in these regions are now seeing a need for earlier diagnosis, improved surveillance, and treatment directed at typhoid and paratyphoid fever.

Because antibody-based assays—from rapid lateral-flow tests to lab-based ELISA—are often easy to use, produce results quicker, and are cheaper, they are ideal for large-scale screening, outbreak response, and clinical routine. The availability of antibodies has increased accessible diagnostic alternatives where culture-based and molecular diagnostics are impracticable. Typhoid antibody testing is becoming an essential part of the effort to reduce the diseases and reduce and support overall global health security initiatives.

Key Trends & Drivers

• Innovative Rapid & Point-of-Care Diagnostics: The drive for diagnostics that provide reliable results at the point of care is changing typhoid testing. Next-generation tests in the lateral-flow family of tests, more sensitive ELISA testing kits, and more straightforward sample-preparation workflows are improving the implementation of antibody-based tests in outpatient clinics, community screening, and response to outbreaks. Innovations to reduce operator reliance, reduce time to results to minutes, and allow testing outside of centralized laboratories have the potential for better implementation and use by primary care providers and public health teams.

• Antimicrobial Resistance (AMR) and the Need for Surveillance: Increasing awareness of antimicrobial resistance (AMR) in Salmonella enterica serovar Typhi has highlighted the need for increased use of diagnostics in surveillance as well as stewardship. While antibody testing does not report susceptibility information, rapid serological screening means that alerts can be raised about probable cases for confirmation and for sequence collection. Importantly, it supports guided antibiotic use and AMR monitoring programs. When also recognizing investments made by governments and international health organizations into a surveillance structure, the demand for rapidly deployable screening tools is evident.

• Limitations & Regulatory Expectations: While diagnostic tests may function well, traditional antibody tests continue to have common utility and technical challenges, such as variable sensitivity/specificity, cross-reactivity with non-typhoidal Salmonella and/or other infections, and the challenges in determining if a patient has a current, as opposed to a historical, infection. The demand for more evidence-based higher-performance products by regulatory authorities and procurers, however, is increasing. The onus is on manufacturers to invest the time and money to conduct clinical studies and build quality systems, as well as post-market surveillance for compliance with government/global health funders procurement standards.

• Expanding Healthcare Access and Diagnostic Infrastructure in Endemic Regions: Economic growth and purposeful expenditures on primary health care and laboratory networks in endemic countries are improving access to diagnostics. Community health programs, donor-funded programs, and national disease-control strategies that emphasize the management of fevers and surveillance of enteric diseases generate an environment that promotes the expanded use of antibody-based typhoid tests.

Report Scope

SWOT Analysis

• Strengths: The market for typhoid antibody testing is advantageously affected by quick turnaround times and simplicity of format, with lateral-flow immunoassays generating results in a matter of minutes. These characteristics support prompt and on-the-spot clinical and field decision-making. Because antibody-based tests represent a cost-effective alternative to molecular diagnostics, they hold great utility for low-resource conditions. They are easily placed and deployed in field settings because of limited cold-chain requirements and straightforward workflows. These features make antibody tests appropriate for outbreak response, community screening, and remote clinics.

• Weaknesses: However, the market has the potential for sizeable weaknesses. The diagnostic performance of individual tests also varies widely, as sensitivity and specificity range dramatically depending on the specifics of the test/product and the surrounding health landscape. Confounding conditions lead to cross-reactivity with other infections, and an understanding of the persistence of antibodies is necessary in different etiologies. The availability of laboratory confirmed diagnosis, in an instance where tests do not provide pathogen isolation or subsequent antimicrobial susceptibility data, further limits practical implementation for guiding treatment and supporting AMR surveillance.

• Opportunities: There are significant opportunities for growth and innovation in the market. Continued improvements in biomarker research and assay design can increase diagnostic precision, and the deployment of multi-marker or multiplex platforms will enable clinicians to address a much wider spectrum of febrile illnesses, such as dengue and malaria, in addition to typhoid. The existing public health programs, donor-funded initiatives, and government procurement efforts are creating large-scale adoption opportunities. Also, the integration with digital health tools for real-time reporting, geolocation, and outbreak monitoring will further enhance the value proposition for antibody testing.

• Threats: At the same time, the market is facing several threats or potential hurdles for long-term viability. Gold-standard diagnostics, including molecular tests and automated blood culture systems, continue to advance, and increased affordability may decrease reliance on antibody-based methods. Escalating regulatory requirements and procurement criteria are increasing the costs of development and timelines for manufacturers. Additionally, successful vaccination and sanitation campaigns may decrease the incidence of disease in endemic regions, which may shrink the market. Finally, misuse or over-reliance on antibody tests without confirmatory diagnostics could lead to ineffective treatments that contribute to AMR and clinician disillusionment.

List of the prominent players in the Typhoid Antibody Testing Market:

• Abbott Laboratories
• Diagnostic BioSystems
• Siemens Healthineers
• BD (Becton Dickinson and Company)
• HoffmannLa Roche
• Thermo Fisher Scientific
• Hycult Biotech
• Bio-Rad Laboratories
• Medmix
• Zhejiang Dian Diagnostics
• Meridian Bioscience
• Creative Diagnostics
• BioMérieux
• InBios International
• DiaSorin
• Grifols
• Adaltis
• Others

The Typhoid Antibody Testing Market is segmented as follows:

By Product Type

• Rapid Serological Tests
  • Hem-agglutination & Co-agglutination
  • Counter Immunoelectrophoresis
• Typhidot Test
• Widal Test

By End-User

• Hospitals
• Serological Testing Centers
• Clinics
• Diagnostic Centers
• Others

Regional Coverage:

North America

• U.S.
• Canada
• Mexico
• Rest of North America

Europe

• Germany
• France
• U.K.
• Russia
• Italy
• Spain
• Netherlands
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• New Zealand
• Australia
• South Korea
• Taiwan
• Rest of Asia Pacific

The Middle East & Africa

• Saudi Arabia
• UAE
• Egypt
• Kuwait
• South Africa
• Rest of the Middle East & Africa

Latin America

• Brazil
• Argentina
• Rest of Latin America